Project Grant HT94252410780
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$500K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
The Defense Health Agency awarded a $899,999 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care assay for monitoring rejection and immunosuppression in vascularized composite allotransplantation (VCA) recipients. The project aims to transform healthcare for service members and the public through innovative biomedical research focused on medical solutions for the battlefield. The...
The Defense Health Agency awarded a $410,000 Project Grant titled "Localized and Inflammation-Responsive Immunotherapy of VCA Rejection" to The Geneva Foundation, a 501(c)3 non-profit organization that supports medical research and education for the U.S. military. This grant is part of the "Military Medical Research and Development" program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for Service Members and the public...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
The Defense Health Agency awarded a $409,792 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc. to develop a "HIGHLY PENETRATING NANODISC FOR TARGETING FIBROBLAST PLASTICITY IN PULMONARY FIBROSIS". The grant, with a performance period from March 2025 to March 2027, supports advanced biomedical research focused on transforming healthcare for military service members and the public. Brigham & Women's Hospital...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
The U.S. Department of Defense's Defense Health Agency (DHA) awarded a $750,000 Project Grant to Stanford University to implement a spatial and single-cell multiplexed platform for the development of targeted therapies for vascularized composite allotransplantation. The funding is provided through the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports advanced biomedical research to transform healthcare for military service members and the broader...
The Johns Hopkins University received a $722,589.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on localized and inflammation-responsive immunotherapy of vascular composite allograft (VCA) rejection. The 3-year project, which commenced on July 1, 2023 and is slated for completion by June 30, 2026, aims to transform healthcare for service members and the American public by investigating innovative...